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Purpose: A variety of dose/fractionation schemes are used for 
adjuvant radiotherapy (RT) in node positive (Stage III) 
melanoma. A prospective randomized study of adjuvant nodal 
radiation for high-risk Stage III melanoma used 2.4 Gy x 20 
fractions in four weeks. The largest retrospective series to date 
used a hypofractionated scheme of 6 Gy x 5 fractions over 2.5 
weeks. No randomized comparison of these has been reported. 
At our institution, either fractionation is used based on physician 
and patient preference. We sought to compare clinical outcomes 
using hypofractionated and conventional radiotherapy for node 
positive melanoma. 
Methods and Materials: Patients who received adjuvant 
radiation for node positive melanoma between 2009 and 2014 
were included. Kaplan–Meier estimates of overall survival (OS) 
and 95% confidence intervals (CI) were obtained. Logistic 
regression was used to explore the association between patient, 
tumour and treatment factors for the outcomes of these 
patients. 
Results: Forty-one patients were included in the final analysis. 
Median follow up was two years. Sixty-one percent of patients 
were treated with hypofractionated radiotherapy (6 Gy x 5 for 
23 patients and 6 Gy x 6 for two patients) and the remainder 
received conventional fractionation 40-60 Gy in 15-30 fractions). 
Treatment sites included the axilla (39%), groin (29%) and 
head/neck (32%). No significant differences in stage, number of 
involved nodes, largest node, nodal location, or extracapsular 
extension were present between the two groups. Comparing the 
hypofractionated versus conventional groups, there was no 
significant difference in regional control (76 versus 84%), distant 
control (48 versus 44%) or overall survival (67 versus 62%). 44% 
were referred to a specialty clinic for management of 
lymphedema in the hypofractionated group versus 19% in the 
conventional group (HR 2.56, 95% CI 0.85-7.68, p = 0.094). 
Conclusions: Hypofractionated and conventional radiotherapy 
results in similar rates of disease control at two years in node 
positive melanoma. A trend towards higher referrals for 
lymphedema management was observed in the hypofractionated 
group. Future work should prospectively compare outcomes and 
toxicity for giving patients best advice for hypofractionation 
compared with standard treatment. 
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Purpose: Stage III cutaneous melanoma incorporates a 
heterogeneous patient group with node positive disease. 
Adjuvant radiotherapy decreases regional recurrence but its use 
is sporadic, in part due to a high competing risk of distant failure. 
This study aimed to assess our institutional practice patterns, 
evaluate clinical outcomes post radiotherapy, and identify risk 
factors for distant metastases in Stage III melanoma patients. 
Methods and Materials: Patients who received adjuvant 
radiation for node positive melanoma between 2009 and 2014 
were included. Kaplan-Meier estimates of overall survival (OS) 
and 95% confidence intervals (CI) were obtained. Logistic 
regression was used to explore the association between patient, 
tumour and treatment factors for the outcomes of these 
patients. 
Results: Forty-one patients were analyzed. Median follow up was 
two years. Sixty-one percent presented with palpable nodal 
disease. Sixty-six percent had a sentinel lymph node procedure 
prior to completion nodal dissection. Patients had an average of 
three involved lymph nodes and 23 total lymph nodes removed. 
Extracapsular extension was present in 51% of patients. Sixty-one 
percent of patients received hypofractionated radiotherapy (30 
Gy/5 fractions or 36 Gy/6 fractions over 2.5-3 weeks) versus 39% 
who received conventional fractionation (typically 48 Gy/20 
fractions). Regional radiation targets included the axilla (39%), 
head and neck (32%) and groin (29%). At two years, regional 
control was 82% and distant control was 46%. Median overall 
survival was 3.7 years. All patients who experienced a regional 
failure post-RT developed distant metastases and died of 
melanoma. All patients who were free of distant failure had 
regional control. Development of distant metastases was strongly 
associated with extracapsular extension (HR 4.0, 95% CI 1.8-8.7, 
p < 0.0001). T-stage, N-stage, RT dose, neurotropism, nodal size, 
location and number involved were not associated with regional 
or distant control. 
Conclusions: Patients who receive adjuvant radiotherapy for 
node positive melanoma have high rates of regional control but 
are prone to distant failure. Regional failure is a harbinger of 
distant disease. Extracapsular extension also predicts distant 
failure in this population. 
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Purpose: Prostate cancer resulted in approximately 4100 deaths 
in Canada in 2015. The advent of new systemic agents for 
treatment of metastatic castration-resistant prostate cancer 
demonstrating overall survival benefits has changed the 
landscape of care, and may impact the demand for and provision 
of palliative radiation to bone (PRTB) in this population. The 
purpose is to describe the use of PRTB in patients who died of 
prostate in British Columbia between 2003 and 2015. 
Methods and Materials: All patients that died of prostate cancer 
in the time period were identified from a population-based 
provincial cancer registry. Exclusion criteria included: other sites 
of cancer diagnosis, lack of adenocarcinoma histology, RT to non-
bone sites or of non-palliative intent. Patient and treatment 
characteristics were analyzed using SAS. PRTB use for the first 
and last courses was calculated by year of death, overall, and by 
region. Survival was calculated for the following: from first 
course of PRTB to death, from last course of PRTB to death, and 
by treatment year. To assess the adequacy of provision of PRTB 
in this population, the geographical distribution of the incidence 
of prostate cancer was compared with the treatment frequency 
across the province.  
Results: Out of 23,260 prostate cancer patients who died 
between 2003 and 2015, 5701 had prostate adenocarcinoma as 
their only primary cancer diagnosis. The median age at the time 
of death was 81 and median survival after diagnosis was 5.2 
years. Utilization of PRTB prior to death was 38.6% (2203 
patients), with a trend to increase overtime from 29% in 2003, to 
44% in 2015. Multiple courses of PRTB were frequent, with 
patients receiving two, three, four or more courses of PRTB in 
25%, 13%, and 14% of cases respectively. Survival after first 
course of PRTB to prostate cancer death was 38.6% at one year, 
and 2.3% at five years, and a median of 8.5 months. Median 
survival after first course of PRTB increased slightly over the 
study years for those dying of prostate cancer from 8.2 months 
in 2003-5 to 9.4 months in 2013-15 (p = 0.04). For last course of 
PRTB, 2% were treatment within the last four weeks of their life. 
Use of PRTB varied with region and was lower in some rural 
areas.  
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Conclusions: Only 38.6% of patients that died of prostate cancer 
received palliative RT to bone (PRTB) prior to death, but this 
increased overtime to 44% by 2015. It is difficult to know the 
proportions of prostate cancer patients that have indications for 
PRTB, and whether this utilization reflects appropriate access. 
This study shows that majority of patients that die of prostate 
cancer do so within a year of their first course of palliative RT to 
bone, and only a minority of patients are treated within four 
weeks of death. 
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Purpose: Many patients with cancer require home-based 
assistance which may be provided by a family or lay caregiver. 
Shorter inpatient hospital stays, limited home care resources, 
and a preference to die at home, result in unprecedented 
demands on these informal caregivers (IC). We sought to identify 
a questionnaire which can be used to characterize quality of life 
of those caring for a palliative oncology population. 
Methods and Materials: English publications describing 
instruments used to measure distress in IC of cancer patients 
were identified via literature search. Eligibility criteria included 
measurement of QOL during caregiving, prior to the patient’s 
death, unrelated to a specific procedure. Characteristics of 
instruments were summarized and factors associated with 
increased IC distress were tabulated 
Results: Sixteen questionnaires were identified measuring 
objective and/or subjective burden. Tools contained up to 53 
questions and required < 30 minutes for self-administration. 
Patient factors associated with increased IC burden included 
poor performance status, rapid clinical deterioration, and 
symptom severity. IC factors associated with increased burden 
included younger age, spousal relationship, female gender, 
lower education, preexisting financial strain, and lack of social 
supports. Of the tools reviewed, the Caregiver Quality of Life 
Index in Cancer (CQOLC) was selected for further study due to 
its ease of use and comprehensiveness. The CQOLC has been 
validated in IC of outpatients as well as in home hospice patients. 
Each of its 35 items maps to a specific domain which facilitates 
subsequent referral to support services. 
Conclusions: Future research will utilize the CQOLC to screen IC 
of patients referred to a dedicated palliative radiotherapy 
program. Additional items will explore potential correlates with 
reported burden. Early identification of vulnerable IC should 
facilitate delivery of appropriate support, minimizing the degree 
of distress experienced. 
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Purpose: The optimal dose for palliative whole brain 
radiotherapy (WBRT) continues to be debated. Common 
regimens include 20 Gy in five and 30 Gy in 10 fractions. We 
aimed to identify factors associated with WBRT dose schedules, 
hypothesizing that clinical prediction of survival (CPS) would 
influence prescribing practice. 
Methods and Materials: Demographic and clinicopathologic data 
were collected for consecutive patients with brain metastases 
receiving WBRT through a dedicated palliative radiation oncology 
clinic. At initial consultation, CPS were prospectively collected 
from treating radiation oncologists. Karnofsky Performance 
Status (KPS) and Mini-Mental State Examination (MMSE) were 
available for 88.6% and 75.1%, respectively. Dose fractionation 
was collected and summary statistics calculated. Parameters 
were assessed for association with five-fraction schedules using 
binary logistic regression, with odds ratios and 95% CI reported. 
Results: One hundred and ninety-three patients underwent 
WBRT (n = 102 from 2010-2012; n = 91 from 2013-2014); 38/193 
had 48 extracranial sites irradiated concurrently. 46.1% were 
male, mean age was 64.7 years (SD 11.6), and 63.7% had lung 
cancer. Median KPS was 70 (range 20-100) and median MMSE 
score was 27/30 (range 13-30). Median CPS and actual survival 
were 150 days (range 21-730d) and 96 days (range 11-1029d), 
respectively. 18.7% received WBRT within 30 days of death. 
78.2% (151/193) and 17.6% (34/193) received 5 and 10 fractions, 
respectively; 8/193 were prescribed other schedules. On 
multivariate analysis, patients with KPS ≤ 70 were 5.93 times 
more likely to have received 5 fractions (95% CI 2.51-14.1; p < 
0.0001). Those treated 2010-2012 were less likely to have 
received 5 fractions (OR 0.28; 95% CI 0.11-0.68; p = 0.005). CPS, 
age, gender, MMSE, histology, disease extent, and extracranial 
irradiation were not predictive of WBRT schedule. 
Conclusions: Patients treated with WBRT with KPS ≤ 70 and those 
treated more recently were more likely to receive five fractions. 
Oncologist CPS was not a statistically significant predictor of 
schedule in this cohort. 
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Purpose: Quality of life (QOL) can be compromised in patients 
with bone metastases. The use of validated QOL instruments is 
necessary to accurately measure QOL outcomes in this 
population. This study investigated the validity, reliability and 
responsiveness of the EORTC QLQ-BM22 module with the EORTC 
QLQ-C15-PAL instrument in bone metastases. 
Methods and Materials: The studied patients underwent 
palliative radiotherapy to bone metastases as part of the Phase 
III randomised NCIC CTG SC 23 trial. Multitrait scaling analysis 
was performed to determine convergent and divergent validity 
among the scales. Pearson coefficients were calculated to 
determine the correlation between the items of the two 
